Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Lecompte

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
La Tunisie Medicale|April 18, 2003
[Platelet inhibitors: old and new]Thomas Lecompte
La Revue Du Praticien|July 16, 2004
[Prescription and surveillance of antithrombotic agents. Part 2: antiplatelet agents]Thomas Lecompte
Nephrologie & Therapeutique|March 22, 2007
[New complete blood count parameter to evaluate iron status of haemodialysis patients]Sylvain Salignac, Thomas Lecompte
European Heart Journal Open|September 26, 2022
Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias familyMickaël Noyé, Thomas Lecompte
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|June 13, 2006
Antiplatelet agents and perioperative bleedingThomas Lecompte, Jean-François Hardy
Revue Medicale Suisse|December 6, 2018
[Antithrombotic treatments and inherited bleeding disorders]ALessandro Casini, Pierre Fontana, Thomas Lecompte
Pathophysiology of Haemostasis and Thrombosis|July 11, 2003
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulabilityVéronique Regnault, Suzette Béguin, Thomas Lecompte
British Journal of Haematology|November 14, 2008
Multiple myeloma with unusual inclusionsBirgit Frotscher, Sylvain Salignac, Thomas Lecompte
Thrombosis Research|August 26, 2023
Assessment of the individual determinants of two fibrinolysis assays, GFC and ECLT in platelet-depleted plasma and derived euglobulin fraction respectivelyMarion Bareille, Thomas Lecompte, François Mullier
Arthritis and Rheumatism|February 2, 2008
Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et alDenis Wahl, Thomas Lecompte, Henri Bounameaux
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
La Tunisie Medicale|April 18, 2003
[Platelet inhibitors: old and new]Thomas Lecompte
La Revue Du Praticien|July 16, 2004
[Prescription and surveillance of antithrombotic agents. Part 2: antiplatelet agents]Thomas Lecompte
Nephrologie & Therapeutique|March 22, 2007
[New complete blood count parameter to evaluate iron status of haemodialysis patients]Sylvain Salignac, Thomas Lecompte
European Heart Journal Open|September 26, 2022
Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias familyMickaël Noyé, Thomas Lecompte
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|June 13, 2006
Antiplatelet agents and perioperative bleedingThomas Lecompte, Jean-François Hardy
Revue Medicale Suisse|December 6, 2018
[Antithrombotic treatments and inherited bleeding disorders]ALessandro Casini, Pierre Fontana, Thomas Lecompte
Pathophysiology of Haemostasis and Thrombosis|July 11, 2003
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulabilityVéronique Regnault, Suzette Béguin, Thomas Lecompte
British Journal of Haematology|November 14, 2008
Multiple myeloma with unusual inclusionsBirgit Frotscher, Sylvain Salignac, Thomas Lecompte
Thrombosis Research|August 26, 2023
Assessment of the individual determinants of two fibrinolysis assays, GFC and ECLT in platelet-depleted plasma and derived euglobulin fraction respectivelyMarion Bareille, Thomas Lecompte, François Mullier
Arthritis and Rheumatism|February 2, 2008
Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et alDenis Wahl, Thomas Lecompte, Henri Bounameaux
Pageof 17